Antinociceptive Effect of Spirocyclopiperazinium Salt Compound DXL-A-24 and the Underlying Mechanism

Neurochem Res. 2019 Dec;44(12):2786-2795. doi: 10.1007/s11064-019-02899-x. Epub 2019 Nov 6.

Abstract

The antinociceptive effects of spirocyclopiperazinium salt compound DXL-A-24 on neuropathic pain and chemical-stimulated pain were investigated in this study. After the administration of DXL-A-24, the paw withdrawal latency (PWL) and mechanical withdrawal threshold (MWT) were increased in rats suffering from neuropathic pain (chronic constriction injury, CCI) on days 1, 3, 5, 7 and 14 after surgery, and pain responses were inhibited in mice stimulated with chemicals (formalin or acetic acid). In the analysis of antinociceptive targets, the effect of DXL-A-24 was blocked by a peripheral nicotinic acetylcholine receptor (nAChR) antagonist (hexamethonium, Hex) or α7 nAChR antagonist (methyllycaconitine, MLA) in the formalin test. Meanwhile, the effect of DXL-A-24 was also blocked by a peripheral muscarinic acetylcholine receptor (mAChR) antagonist (atropine methylnitrate, Amn) or M4 mAChR antagonist (tropicamide, TRO). The antinociceptive signalling pathway was explored using molecular biology methods in ipsilateral dorsal root ganglions (DRGs) of CCI rats after the administration of DXL-A-24 for 7 days. Western blot analyses showed that the increased levels of phosphorylation of calcium/calmodulin-dependent protein kinase II alpha (CaMKIIα) and cAMP response element-binding protein (CREB) were eliminated, and the qRT-PCR assay showed that the increase in the expression of Tumor necrosis factor alpha (TNF-α) mRNA was reduced. Meanwhile, immunofluorescence staining revealed that the increase in calcitonin gene related peptide (CGRP) expression was inhibited by the administration of DXL-A-24, and the effect was blocked by MLA or TRO. In conclusion, DXL-A-24 exerts significant antinociceptive effects on neuropathic pain and chemical-stimulated pain. The antinociceptive effect of DXL-A-24 is probably attributed to the activation of peripheral α7 nAChR and M4 mAChR, the subsequent inhibition of the CaMKIIα/CREB signalling pathway, and finally the inhibition of TNF-α and CGRP expression.

Keywords: M4 mAChR; Neuropathic pain; Signalling pathway; Spirocyclopiperazinium salt compound DXL-A-24; α7 nAChR.

MeSH terms

  • Acetic Acid
  • Analgesics / therapeutic use*
  • Analgesics / toxicity
  • Animals
  • Calcitonin Gene-Related Peptide / metabolism
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2 / metabolism
  • Cyclic AMP Response Element-Binding Protein / metabolism
  • Female
  • Formaldehyde
  • Male
  • Mice, Inbred ICR
  • Neuralgia / drug therapy*
  • Nociceptive Pain / chemically induced
  • Nociceptive Pain / drug therapy*
  • Piperazines / therapeutic use*
  • Piperazines / toxicity
  • RNA, Messenger / metabolism
  • Rats, Sprague-Dawley
  • Spiro Compounds / therapeutic use*
  • Spiro Compounds / toxicity
  • Tumor Necrosis Factor-alpha / genetics

Substances

  • Analgesics
  • Creb1 protein, rat
  • Cyclic AMP Response Element-Binding Protein
  • Piperazines
  • RNA, Messenger
  • Spiro Compounds
  • Tumor Necrosis Factor-alpha
  • Formaldehyde
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2
  • Camk2a protein, rat
  • Calcitonin Gene-Related Peptide
  • Acetic Acid